The initiation of coverage by Baird with an Outperform rating and a high price target suggests a strong bullish outlook for Axsome Therapeutics. This is likely to generate positive investor sentiment and could lead to a short-term increase in the stock price, as market participants may view this as a strong endorsement of the company's potential.